Sedor Pharma bags nod for room temp-stable seizure med Sesquient

When it comes to seizure treatment, timing is key. Now, armed with a nod for an easily-storable version of the status epilepticus drug fosphenytoin, Sedor Pharmaceuticals aims to get the potentially life-saving treatment into places where patients can be treated quickly.

The FDA this week gave a thumbs up to Sedor's room temperature-stable injectable seizure med Sesquient (fosphenytoin sodium) to treat status epilepticus in adults and children, making it the only FDA-approved fosphenytoin drug that can be stored in point-of-care settings like emergency rooms, ambulances, long-term care facilities and more, the drugmaker said.